These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20649763)

  • 1. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients.
    Goto S; Fujii H; Hamada Y; Yoshiya K; Fukagawa M
    Ther Apher Dial; 2010 Aug; 14(4):417-23. PubMed ID: 20649763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
    Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
    Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
    Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
    Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Lowering Dialysate Calcium Concentration on Bone Metabolic Markers in Hemodialysis Patients With Suppressed Serum Parathyroid Hormone: A Preliminary Study.
    Niwa H; Fukasawa H; Ishibuchi K; Kaneko M; Yasuda H; Furuya R
    Ther Apher Dial; 2018 Oct; 22(5):503-508. PubMed ID: 29923680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
    Nowak Z; Konieczna M; Wańkowicz Z
    Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
    Janckila AJ; Lederer ED; Price BA; Yam LT
    Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
    Nakashima A; Yorioka N; Mizutani T; Yamagata Z; Ueno T; Takasugi N
    Nephron Clin Pract; 2005; 99(3):c78-85. PubMed ID: 15665550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of bone resorption markers in hemodialysis patients.
    Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y
    Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
    Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
    Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.
    Taki K; Tsuruta Y; Niwa T
    Am J Nephrol; 2007; 27(1):30-5. PubMed ID: 17215572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.